NASDAQ: PPCBPropanc Biopharma Inc Stock
$2.87
Updated Aug 15, 2025
PPCB Price
$2.87
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$2.82
52 Week High
$4.50
P/E
0x
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$55.21M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.25
Operating Cash Flow
-$638k
Beta
N/A
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PPCB's potential to beat the market
- PPCB doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PPCB
RankedUnranked of 482
RankedUnranked of 482
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $13.15 | A | |
| $39.51 | A | |
| $12.27 | A |
Be the first to know about important PPCB news, forecast changes, insider trades & much more!
PPCB News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PPCB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PPCB was unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PPCB is good value based on its earnings relative to its share price (0x), compared to the US market average (35.99x)
P/E vs Market Valuation
PPCB is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more PPCB due diligence checks available for Premium users.
Valuation
PPCB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
-120.52x
Market
35.99x
PPCB is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PPCB is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
PPCB's financial health
Profit margin
Revenue
$0.0
Net Income
-$54.1M
Profit Margin
0%
PPCB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$22.5M
Liabilities
$4.4M
Debt to equity
0.25
PPCB's short-term assets ($9.74M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PPCB's short-term assets ($9.74M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PPCB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$136.2k
Investing
$0.0
Financing
$187.5k
PPCB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
Propanc Biopharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.